BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 27, 2007
 |  BioCentury  |  Strategy

Exubera not accreting

The Incretin Movement

Exubera not accreting

While the new incretin-based additions to the Type II diabetes arsenal eclipsed half a billion dollars in sales in the first half of 2007, not all recent entrants to the Type II market have been adopted with the same enthusiasm.

Pfizer Inc. had high hopes for Exubera in January 2006 when it agreed to pay sanofi-aventis Group (Euronext:SAN; SNY, Paris, France) $1.3 billion for exclusive rights to the product, the first of a wave of intranasal and oral insulin products in development. But when the pharma released its first sales report on the product, it revealed Exubera posted only $4 million in 2Q07 sales.

Explaining the lack of uptake, doctors cite a lack of awareness about the product,...

Read the full 611 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >